title: Sorafenib-induced erythema multiforme: three cases.
authors.forename: Mio
authors.initials: M
authors.lastname: Namba
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Tsunemi
authors.forename: Makoto
authors.initials: M
authors.lastname: Kawashima
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000556:secondary; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology*; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib